Findings from Genentech Inc. Provides New Data about Breast Cancer (Patterns and Predictors of First-line Taxane Use In Patients With Metastatic Triple-negative Breast Cancer In Us Clinical Practice): Oncology – Breast Cancer

Biotech Business Daily

2021 SEP 27 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Daily -- Data detailed on Oncology - Breast Cancer have been presented. According to news reporting out of San Francisco, California, by NewsRx editors, research stated, “We investigated first-line (1L) treatment patterns and predictors of taxane use to better understand the evolving metastatic triple-negative breast cancer (mTNBC) treatment landscape. This retrospective analysis of the Truven Health MarketScan® (Somers, NY, USA) Database included women with mTNBC who received 1L therapy within six months of diagnosis (January 2005-June 2015).”

Financial support for this research came from Hoffmann-La Roche.

Our news journalists obtained a quote from the research from Genentech Inc., “Multivariate logistic regression models identified predictors of taxane use, adjusting for prognostic factors. A total of 2271 women with newly diagnosed mTNBC received 1L treatment during the study period. Half received a 1L taxane (53%), more often in combination than as monotherapy (58% versus 42%), though this varied by specific taxane. Nab-Paclitaxel monotherapy increased substantially after 2010. More recent treatment year (odds ratio, 2.16 (95% CI 1.69-2.76]) and number of metastases (>= 3 versus 1:1.73 (1.25-2.40)) predicted taxane monotherapy versus combination. Having a health maintenance organization versus a preferred provider organization plan predicted less nab-paclitaxel versus paclitaxel (0.32 (0.13-0.80)) or docetaxel (0.30 (0.10-0.89)) use. More recent index year (2011-2015 vs. 2005-2010) was the only predictor favoring nab-paclitaxel versus paclitaxel (2.01 (1.26-3.21)) or docetaxel (3.63 (2.11-6.26)). Taxane-containing regimens remained the most common 1L mTNBC treatments.”

According to the news editors, the research concluded: “Paclitaxel and nab-paclitaxel use changed substantially over time, with nab-paclitaxel use associated with insurance coverage.”

For more information on this research see: Patterns and Predictors of First-line Taxane Use In Patients With Metastatic Triple-negative Breast Cancer In Us Clinical Practice. Current Oncology, 2021;28(4):2741-2752. Current Oncology can be contacted at: Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.

Our news journalists report that additional information may be obtained by contacting Patricia Luhn, Genentech Inc., San Francisco, CA 94080, United States. Additional authors for this research include Joyce O’Shaughnessy, Leisha A. Emens, Stephen Y. Chui, Shih-Wen Lin, Wei Wang, Kenneth Russell, Carlos Flores Avile and Andreas Schneeweiss.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3390/curroncol28040239. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.